Dr. Bernie spotlights two trials from the ESC 2019 Congress in Paris: AFIRE indicates limited benefits of aspirin while DAPA signals a new approach to treating congestive heart failure.
VITAL and REDUCE-IT trials conclude with different results on the impact of Omega-3 on the reduced risk of cardiovascular disease.
8 min
About Practice Impact Extra
From the publisher's feed
Dr. Bernard Monteleone, former Head of Cardiology at St. Francis Hospital in New York, gives an informed analysis of highly-anticipated trials and whether or not their findings could impact clinical…
practice guidelines and reduce the risk of cardiovascular disease.